Spinal Simplicity’s IntraLink injectable device for disc degradation earned the FDA’s breakthrough device designation, according to an Aug. 14 news release.
IntraLink uses self-polymerizing plant-derived compounds that attach to collagen fibrils in the disc. It mechanically supports the disc to inhibit excess motion and stabilize the spinal joint.
With breakthrough designation IntraLink will get priority FDA review and streamlined, collaborative communication through the premarket review process.
